Could a probiotic protect Insulin-Making cells in newly diagnosed type 1 diabetes?

NCT ID NCT04335656

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a probiotic called Lactiplantibacillus plantarum (Lp299v) can reduce inflammation and help preserve the body's ability to make insulin in people newly diagnosed with type 1 diabetes. The study includes 60 participants aged 3 to 45 who were diagnosed within the last 100 days. Half will take the probiotic daily for 6 months, and the other half will take a placebo, with researchers measuring changes in inflammation and insulin production.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Lactiplantibacillus plantarum (Lp299v) probiotic
What this could lead to
If it works, this could point toward a way to help preserve the body's own insulin production in people newly diagnosed with type 1 diabetes.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. The probiotic may not reduce inflammation or slow disease progression as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.